Jagsonpal Pharmaceuticals Acquires 85% Stake in Aequitas Healthcare Marking Strategic Entry into Hospital Segment
Jagsonpal Pharmaceuticals Ltd. has entered into a definitive agreement for the acquisition of an 85% equity stake in Aequitas Healthcare Private Limited, gaining a significant foothold in India's hospital pharmaceutical segment. This move aligns with Jagsonpal’s long-term strategy to strengthen its presence within the rapidly growing healthcare ecosystem.Aequitas, which is based in Mumbai, specializes in the sale and distribution of pharmaceutical products specifically catering to hospitals. The acquisition aims to pivot Jagsonpal from a legacy retail prescription player into an Omnichannel Specialty healthcare business in India.
The total consideration for the 85% stake is set at Rs. 20.8 crores, which will be funded through internal accruals by Jagsonpal. The remaining 15% stake will be retained by the current Directors of Aequitas, who will continue to be involved with the business post-acquisition.
Aequitas itself has a robust track record, having been founded in 2017 and servicing leading hospital chains across India. For fiscal year 2026 (FY26), Aequitas generated revenues of Rs. 53 crores.
Manish Gupta, Managing Director at Jagsonpal, commented on the transaction, stating that acquiring Aequitas provides a ready platform for a meaningful presence in the hospital segment. He added that Jagsonpal's portfolio of established brands is expected to benefit greatly from Aequitas’ strong institutional relationships, aiming to deliver sustainable long-term value to shareholders.
Mr. Amrut Medhekar, Chief Operating Officer at Jagsonpal, stated that this transaction represents a structurally transformative pivot for the company and reflects its commitment to building scalable, high-quality healthcare delivery in India.
Shailesh Kamat, Director and largest shareholder at Aequitas, expressed his pleasure in associating with Jagsonpal Pharmaceuticals. He noted that over eight years, Aequitas developed a strong hospital business built on quality and deep institutional relationships, and he believes the partnership will unlock new opportunities for employees, customers, and stakeholders.
The acquisition is subject to customary closing conditions and is anticipated to be concluded by July 15, 2026. J Sagar & Associates served as legal Advisors to Jagsonpal for this transaction, while Noverra Partners advised Aequitas.
Key details of the transaction are summarized below:
| Metric | Detail |
|---|---|
| Target Company Acquired | Aequitas Healthcare Private Limited |
| Stake Acquired by Jagsonpal | 85% |
| Total Transaction Value | Rs. 20.8 crores |
| Retained Stake (Aequitas Directors) | 15% |
| Aequitas FY26 Revenue | Rs. 53 crores |
| Expected Closing Date | July 15, 2026 |
JAGSNPHARM Stock Price Movement
Today, shares of Jagsonpal Pharmaceuticals Limited edged higher to close at ₹230.38, gaining 2.96%. The stock traded within an intraday range between ₹221.62 and a high of ₹240, with over 409,303 shares recorded in the trading activity.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.